BPMC

Blueprint Medicines (BPMC) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov^[5], including 1 Phase 3^[1], 3 Phase 2^[2], 1 Phase 1^[3], 1 Phase 4^[4].

Trial NCT04910685^[6] evaluates Elenestinib in Indolent Systemic Mastocytosis with a target enrollment of 534 participants.

No Form 4 insider filings for BPMC were recorded at the SEC in the past 30 days^[7].